Myriad Genetics, Inc.MYGNNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank72
5Y CAGR-6.6%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
-6.6%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 71.17% |
| Q3 2025 | 91.71% |
| Q2 2025 | -330400.00% |
| Q1 2025 | 99.76% |
| Q4 2024 | -92.31% |
| Q3 2024 | 39.78% |
| Q2 2024 | -41.15% |
| Q1 2024 | 16.67% |
| Q4 2023 | 49.10% |
| Q3 2023 | 47.20% |
| Q2 2023 | -112.25% |
| Q1 2023 | -29.31% |
| Q4 2022 | -20.51% |
| Q3 2022 | -148.94% |
| Q2 2022 | 31.22% |
| Q1 2022 | -169.74% |
| Q4 2021 | -130.89% |
| Q3 2021 | 623.40% |
| Q2 2021 | 88.10% |
| Q1 2021 | 0.00% |
| Q4 2020 | 100.00% |
| Q3 2020 | 72.56% |
| Q2 2020 | 51.91% |
| Q1 2020 | -1287.95% |
| Q4 2019 | 59.71% |
| Q3 2019 | -390.48% |
| Q2 2019 | -160.87% |
| Q1 2019 | 165.38% |
| Q4 2018 | 471.43% |
| Q3 2018 | -105.34% |
| Q2 2018 | 14.91% |
| Q1 2018 | -64.49% |
| Q4 2017 | -60.42% |
| Q3 2017 | 528.68% |
| Q2 2017 | 207.14% |
| Q1 2017 | -28.81% |
| Q4 2016 | 591.67% |
| Q3 2016 | -105.13% |
| Q2 2016 | -28.22% |
| Q1 2016 | 7.59% |